The Smarter Monopoly? Orphan Drug Exclusivity vs. Standard Patents—Who Really Wins?
In drug development, the rules of the game are supposed to reward innovation. But the incentives aren’t uniform—and the differences can determine whether patients get n…

Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity
The “cliff” is coming—whether you’re ready or not.
In biologics, the end of exclusivity doesn’t just change pricing. It ch…

Generic competition is supposed to be the end of the story. In pharma, it’s often just the plot twist.
For years, the public narrative around drug patents has been simple: a company invents a medicine, patents expire, generics arrive, prices fall. But …

Patients don’t ask “patent law” questions. They ask survival questions.
In the last few years, the search bar has become a kind of triage desk: “Can I switch from Brand X to Generic Y?” “Will it work the same?” “Will my insurance cover it?” “Is this sa…

Evergreening isn’t just a legal tactic—it’s a timing problem.
In pharma, the brand side doesn’t merely “extend” a patent. It often re-times the battlefield: shifting filings, layering continuations, leveraging new claims, and exploiting the lag between…

Patent cliffs don’t just erode revenue—they rewrite the competitive map.
When a blockbuster’s exclusivity window starts to close, the market doesn’t wait for your next strategy deck. Payers, formularies, and contracting teams move first. Generic and …

OpenAI’s GPT just did something that should make every drug-patent strategist sit up: it “smashed” drug patent cliffs—at least in the way it’s being marketed—by accelerating the search, analysis, and synthesis of what’s protectable, what’s expired, and…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
If you’re in pharma, you already know the headline risk: a Paragraph IV challenge can flip a product’s economics overnight. But the real danger isn’t the fil…

Most people think “patent life” is a single number. In the GCC, it’s a moving target.
If you’re building a launch plan, underwriting market exclusivity, or negotiating licensing terms in the Gulf Cooperation Council (GCC), you don’t just need to know w…